investor-relations

RMD

NYSE: 59.52 +0.00 +0% Volume: 725,500 December 2, 2016
ASX: Volume:
$1.8 Billion
fiscal year 2016


+12%
Adjusted EPS growth over the last five fiscal years

~85%
free cash flow returned to shareholders over the last rolling five years

About ResMed

ResMed (NYSE:RMD) changes lives with award-winning medical devices and cutting-edge cloud-based software applications that better diagnose, treat and manage sleep apnea, chronic obstructive pulmonary disease (COPD) and other chronic diseases. ResMed is a global leader in connected care, with more than 2 million patients remotely monitored every day. Our 5,000-strong team is committed to creating the world’s best tech-driven medical device company – improving quality of life, reducing the impact of chronic disease, and saving healthcare costs in more than 100 countries.

Learn more 2015 Investor Day ResMed Respiratory Medicine 101  

Email Alerts

Email Adress Email Address: *
Mailing Lists *





 
Enter the code shown above.